Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

diluted, compared to a net income of $0.29 per share, basic, and $0.25 per share, diluted, for the same period in 2007. Net income per share for the year ended December 31, 2008 was $0.95 per share, basic, and $0.83 per share, diluted, compared to net income of $1.37 per share, basic, and $1.21 per share, diluted, for the same period in 2007.

The primary drivers of the decrease in net income for the fourth quarter and year ended December 31, 2008 were the increase in R&D, SG&A and intangible amortization expenses, and lower interest income offset by the lower tax expense. Additionally, in the fourth quarter of 2008 we had a $2.3 million charge to write down to fair value our previous corporate headquarters which is currently held for sale.

Operating Highlights

During the three months and year ended December 31, 2008, net sales increased 4.9 percent and 14.0 percent, respectively, compared to the same periods in 2007.

The cost of sales for the three months and year ended December 31, 2008 increased $0.1 million and remained consistent, respectively, as compared to the same periods in 2007. For the three months and year ended December 31, 2008 the cost of sales was $2.1 million and $8.9 million, respectively, compared to $2.0 million and $8.9, respectively, for the same period in 2007.

Investment in our product pipeline and the company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses in the fourth quarter and year ended December 31, 2008 were $43.6 million and $131.7 million, respectively compared to $25.2 million and $72.9 million for the fourth quarter and year ended December 31, 2007, respectively. The quarter increases were due primarily to our investments in our infrastructure related to our development programs, costs to support the Cinryze open label trial and launch related costs, an
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... DIEGO, Aug. 21 NovaRx Corporation announced ... III clinical trial of,Lucanix(R) (belagenpumatucel-L) in the ... The first patient enrolled in the study ... principal investigator at the University,of California, San ...
... Arpida Ltd.,(SWX: ARPN) today announced that the ... its Marketing Authorisation Application (MAA) for,intravenous iclaprim. ... in,the European Union for the treatment of ... is a hospital antibiotic drug candidate with,potent ...
... iron are the basis for much of mankind,s technology, ... this week,s issue of the journal Nature ... and industrial researchers from the UK, USA and Lesotho, ... small amount of another common metal, manganese, to create ...
Cached Biology Technology:NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 4Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3Creating unconventional metals 2
(Date:10/31/2014)... out of a nagging mystery about the development of animal ... why animal species didn,t flourish sooner, once sufficient oxygen covered ... of the Proterozoic period, about 800 million years ago — ... researchers think there also was plenty of oxygen? , Well, ... , In a study published Oct. 30 in Science ...
(Date:10/31/2014)... green space in cities is good for attracting species, but ... environments, a University of Iowa study has found. , The ... in Iowa, and recorded the abundance of two insects that ... of the trees, black cherry and black walnut, they didn,t ... fruit flies that feed on the walnuts and black cherries ...
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... Extract Protein Array Kit is designed for ... The expression of a protein in an ... antibody. When the antibody binds the protein, ... chemiluminescent or fluorescent signal created by directly ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... is specifically formulated for mounting tissue specimens, ... stained with immunohistochemical methods for viewing by ... with chromogens, such as AEC, that are ... dries completely when slides are cover-slipped forming ...
Biology Products: